Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kaleido Biosciences : to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit

10/12/2021 | 07:30am EST

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19.

The webcast of the presentation will be made available in the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 30 days following the event.

About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.

Contacts:

Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com

Investors and Media
Kotaro Yoshida
Argot Partners
212-600-1902
kaleido@argotpartners.com

 


Primary Logo

Source: Kaleido Biosciences

2021 GlobeNewswire, Inc., source Press Releases

All news about KALEIDO BIOSCIENCES, INC.
11/15Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ..
GL
11/12Chardan Adjusts Price Target on Kaleido Biosciences to $11 From $15 on Pipeline Assets ..
MT
11/10Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
GL
11/10Kaleido Biosciences, Inc. to Appoint Alison Long as Chief Medical Officer, Effective De..
CI
11/03JMP Securities Adjusts Price Target on Kaleido Biosciences to $22 From $25, Maintains M..
MT
11/01KALEIDO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/01Press Release issued by Kaleido Biosciences, Inc., dated November 1, 2021, furnished he..
PU
11/01Kaleido Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/01Kaleido Biosciences Reports Third Quarter 2021 Financial Results
AQ
10/20NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 1,61 M - -
Net income 2021 -94,6 M - -
Net cash 2021 5,83 M - -
P/E ratio 2021 -1,46x
Yield 2021 -
Capitalization 141 M 141 M -
EV / Sales 2021 83,9x
EV / Sales 2022 145x
Nbr of Employees 82
Free-Float 91,0%
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 3,30 $
Average target price 14,80 $
Spread / Average Target 348%
EPS Revisions
Managers and Directors
Daniel L. Menichella President, Chief Executive Officer & Director
William E. Duke Chief Financial Officer
Theo Melas-Kyriazi Chairman
Johan van Hylckama Vlieg Chief Scientific Officer
Kimberly Hocknell Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-62.53%141
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298